Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Lundin Gold Declares Quarterly Dividends of US$1.15 per Share

View original at finance.yahoo.com
Lundin Gold Declares Quarterly Dividends of US$1.15 per Share Lundin Gold logo (CNW Group/Lundin Gold Inc.) VANCOUVER, BC, Feb. 19, 2026 /CNW/ - Lundin Gold Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The variable dividend will be equal to an amount per share based on at least 50% of the Company's normalized free cash flow during the preceding quarter, less the fixed dividend paid during such period

    80% confidence
  • The quarterly dividend of US$1.15 per share reflects another period of strong performance and cash flow generation at Fruta del Norte and is based on returning 100% of normalized free cash flow, after payment of the fixed dividend, to shareholders

    80% confidence
  • The company continues to demonstrate the quality of FDN and commitment to delivering meaningful returns to shareholders while advancing a growing pipeline of high value opportunities

    80% confidence
  • Fruta del Norte is among the highest-grade operating gold mines in the world

    80% confidence
  • Lundin Gold's ability to consistently return capital to shareholders is driven by the exceptional margins and consistency of the Fruta del Norte asset

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com